Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cencora ( (COR) ) has shared an update.
On June 30, 2025, Cencora, Inc.’s subsidiaries entered into a significant amendment to their Receivables Purchase Agreement, enhancing their securitization facility from $1.45 billion to $1.5 billion and expanding the Accordion Feature to allow for an additional $500 million in commitments, subject to approval. This amendment aims to provide Cencora with increased liquidity and funding flexibility, supporting its ongoing business operations and potentially strengthening its market position.
The most recent analyst rating on (COR) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Outperform.
Cencora’s strong financial performance and positive earnings call results are key strengths, driving the overall score. Technical analysis suggests a neutral to slightly bullish trend, while valuation indicates potential overvaluation, which slightly tempers the overall score.
To see Spark’s full report on COR stock, click here.
More about Cencora
Cencora, Inc. operates in the pharmaceutical industry, focusing on the sale of pharmaceuticals and related products and services. Its subsidiaries, including AmerisourceBergen Drug Corporation and ASD Specialty Healthcare, LLC, are involved in originating accounts receivables from these sales.
Average Trading Volume: 1,730,127
Technical Sentiment Signal: Buy
Current Market Cap: $57.24B
Learn more about COR stock on TipRanks’ Stock Analysis page.